Bluhmki, Erich

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine

Acute Ischemic Stroke ManagementIntracerebral and Subarachnoid Hemorrhage Research

Cited by 6,684

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)

Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., et al. (1998) · The Lancet

Acute Ischemic Stroke ManagementIntracerebral and Subarachnoid Hemorrhage Research

Cited by 3,662

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

Emberson, J., Lees, K. R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., Brott, T., Cohen, G., Davis, S., Donnan, G., et al. (2014) · The Lancet

Acute Ischemic Stroke ManagementIntracerebral and Subarachnoid Hemorrhage Research

Cited by 2,737

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 740

Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale

Lansberg, M. G., Schrooten, M., Bluhmki, E., Thijs, V. N., & Saver, J. L. (2009) · Stroke

Acute Ischemic Stroke ManagementStatistical Methods in Clinical Trials

Cited by 220

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ® )

Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 212

Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials

Savitz, S. I., Lew, R., Bluhmki, E., Hacke, W., & Fisher, M. (2007) · Stroke

Acute Ischemic Stroke ManagementStatistical Methods in Clinical Trials

Cited by 119

Dichotomized Efficacy End Points and Global End-Point Analysis Applied to the ECASS Intention-to-Treat Data Set: Post Hoc Analysis of ECASS I

Hacke, W., Bluhmki, E., Steiner, T., Tatlisumak, T., Mahagne, M.-H., Sacchetti, M.-L., & Meier, D. (1998) · Stroke

Acute Ischemic Stroke ManagementStatistical Methods in Clinical Trials

Cited by 109

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial

Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 85

Bootstrap Statistics of ECASS II Data: Just Another post hoc Analysis of a Negative Stroke Trial?

Stingele, R., Bluhmki, E., & Hacke, W. (2001) · Cerebrovascular Diseases

Acute Ischemic Stroke ManagementStatistical Methods in Clinical Trials

Cited by 18